Early research (Phase 1)Study completedNCT03260322
What this trial is testing
A Multiple-dose Study of ASP8374, an Immune Checkpoint Inhibitor, as a Single Agent and in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors
Who this might be right for
Advanced Solid Tumors
Astellas Pharma Global Development, Inc. 169